Cost-effectiveness of strengthening blood pressure classification in South Korea: comparing the 2017 ACC/AHA and KSH guidelines
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Hypertension is a significant risk factor for cardiovascular disease (CVD), with hypertension-related deaths increasing annually. While South Korea uses the Korean Society of Hypertension (KSH) guideline of 140/90 mmHg, the American College of Cardiology (ACC) and American Heart Association (AHA) updated their guidelines in 2017 to 130/80 mmHg. This study evaluates the cost-effectiveness of transitioning to the 2017 ACC/AHA guidelines by estimating early treatment impacts and potential CVD risk reduction.A Markov state-transition simulation model with a 10-year horizon was used to estimate cost-effectiveness, focusing on strengthening target blood pressure. Quality-adjusted life years (QALYs) served as the measure of effectiveness. Cohorts of 10,000 individuals representing South Koreans in their 20s through 80s were compared in scenario analyses from the healthcare system perspective. A 4.5% annual discount rate was applied to costs and effectiveness. Primary outcomes were incremental cost-effectiveness ratio (ICER) and net monetary benefit (NMB). The willingness-to-pay (WTP) threshold was < KRW 30,000,000/QALY gained. Probabilistic sensitivity analyses (PSAs) addressed model input parameter uncertainties.The base-case analysis showed an ICER value of KRW 1,328,395/QALY gained across all populations. ICER values increased with age, from − KRW 3,138,071/QALY for 20-year-olds to KRW 16,613,013/QALY for individuals over 80. The 60s age group showed the greatest benefit with an incremental QALY gain of 0.46. All scenarios had ICERs below the WTP threshold, with a PSA probability of 98.0% that strengthening blood pressure classification could be cost-effective.This economic evaluation found that adopting the 2017 ACC/AHA guidelines may result in early treatment, reduce the potential incidence of CVD events, and be cost-effective across all age groups. The study findings have implications for policymakers deciding whether and when to revise official guidelines regarding target blood pressure levels, considering the impacts on public health and budgetary concerns.
Abstract
Background Hypertension is a significant risk factor for cardiovascular disease (CVD), with hypertension-related deaths increasing annually. While South Korea uses the Korean Society of Hypertension (KSH) guideline of 140/90 mmHg, the American College of Cardiology (ACC) and American Heart Association (AHA) updated their guidelines in 2017 to 130/80 mmHg. This study evaluates the cost-effectiveness of transitioning to the 2017 ACC/AHA guidelines by estimating early treatment impacts and potential CVD risk reduction. Methods A Markov state-transition simulation model with a 10-year horizon was used to estimate cost-effectiveness, focusing on strengthening target blood pressure. Quality-adjusted life years (QALYs) served as the measure of effectiveness. Cohorts of 10,000 individuals representing South Koreans in their 20s through 80s were compared in scenario analyses from the healthcare system perspective. A 4.5% annual discount rate was applied to costs and effectiveness. Primary outcomes were incremental cost-effectiveness ratio (ICER) and net monetary benefit (NMB). The willingness-to-pay (WTP) threshold was <KRW 30,000,000/QALY gained. Probabilistic sensitivity analyses (PSAs) addressed model input parameter uncertainties. Results The base-case analysis showed an ICER value of KRW 1,328,395/QALY gained across all populations. ICER values increased with age, from −KRW 3,138,071/QALY for 20-year-olds to KRW 16,613,013/QALY for individuals over 80. The 60s age group showed the greatest benefit with an incremental QALY gain of 0.46. All scenarios had ICERs below the WTP threshold, with a PSA probability of 98.0% that strengthening blood pressure classification could be cost-effective. Conclusions This economic evaluation found that adopting the 2017 ACC/AHA guidelines may result in early treatment, reduce the potential incidence of CVD events, and be cost-effective across all age groups. The study findings have implications for policymakers deciding whether and when to revise official guidelines regarding target blood pressure levels, considering the impacts on public health and budgetary concerns.
참고문헌 (35)
- Rapsomaniki E, "Blood pressure and incidence of twelve cardiovascular diseases : lifetime risks, healthy life-years lost, and age-specific associations in 1· 25 million people", Lancet, 383, pp.1899~1911 (2014)[DOI]
- Fuchs FD, "High blood pressure and cardiovascular disease", Hypertension, 75, pp.285~292 (2020)[DOI]
- Stevens SL, "Blood pressure variability and cardiovascular disease : systematic review and meta-analysis", BMJ, 354, pp.i4098~ (2016)[DOI]
- Brunström M, "Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels : a systematic review and meta-analysis", JAMA Intern Med, 178, pp.28~36 (2018)[DOI]
- Ettehad D, "Blood pressure lowering for prevention of cardiovascular disease and death : a systematic review and meta-analysis", Lancet, 387, pp.957~967 (2016)[DOI]
- James PA, "2014 evidence-based guideline for the management of high blood pressure in adults : report from the panel members appointed to the Eighth Joint National Committee(JNC 8)", JAMA, 311, pp.507~520 (2014)[DOI]
- Whelton PK, "2017. APhA", ASH, NMA, pp.PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology, American Heart Association Task Force on Clinical Practice Guidelines
- Kim HL, "The 2022 focused update of the 2018 Korean hypertension Society Guidelines for the management of hypertension", Clin Hypertens, 29, pp.11~ (2023)[DOI]
- Goel H, "Aiming higher in hopes to achieve lower : the European Society of Cardiology", European Society of Hypertension versus the American College of Cardiology, J Hum Hypertens, pp.2019, 33[DOI]
- Weber MA, "Is it time to reappraise blood pressure thresholds and targets? A statement from the International Society of Hypertension—a global perspective", Hypertension, 68, pp.266~268 (2016)[DOI]
- Lee H-Y, "New definition for hypertension", J Korean Med Assoc, 61, pp.485~492 (2018)[DOI]
- Lee H, "2017 ACC", AHA blood pressure classification and cardiovascular disease in 15 million adults of age 20–94 years, 2019, pp.8, 1832~
- Liao CT, "Cost-effectiveness of intensive vs standard blood pressure control among older patients with hypertension", JAMA Netw Open, 6, pp.e230708~ (2023)[DOI]
- Lee YS, "Cost-effectiveness analysis of intensive blood pressure control in Korea", Hypertens Res, 45, pp.507~515 (2022)[DOI]
- HIRA, "Guidelines for economic evaluation of pharmaceuticals in Korea", ~ (2021)
- Husereau D, "Consolidated Health Economic evaluation reporting standards 2022(CHEERS 2022)statement : updated reporting guidance for health economic evaluations", Int J Technol Assess Health Care, 38, pp.e13~ (2022)[DOI]
- Drummond MF, "Methods for the economic evaluation of health care programmes" (2015), Oxford University Press
- Lee YS, "An economic evaluation of intensive hypertension control in CKD patients : a cost-effectiveness study", Clin Hypertens, 28, pp.32~ (2022)[DOI]
- Lee HY, "Cost-effectiveness analysis of hypertension screening in the Korea National Health Screening Program", Korean Circ J, 51, pp.610~622 (2021)[DOI]
- Fan J, "Cost-effectiveness of intensive versus standard blood pressure treatment in older patients with hypertension in China", Hypertension, 79, pp.2631~2641 (2022)[DOI]
- Ke X, "Cost-utility analysis of the integrated care models for the management of hypertension patients : a quasi-experiment in Southwest rural China", Front Public Health, 9, pp.727829~ (2021)[DOI]
- Liang L, "Cost-effectiveness and potential budget impact of non-pharmacological interventions for early management in prehypertensive people : an economic evaluation for China", BMC Public Health, 23, pp.1531~ (2023)[DOI]
- Bress AP, "Cost-effectiveness of intensive versus standard blood-pressure control", N Engl J Med, 377, pp.745~755 (2017)[DOI]
- Das H, "Cost-effectiveness of improved hypertension management in India through increased treatment coverage and adherence : a mathematical modeling study", Glob Heart, 16, pp.37~ (2021)[DOI]
- Wang ST, "Cost-effectiveness analysis of personalized hypertension prevention", J Pers Med, 13, pp.1001~ (2023)[DOI]
- Kim HC, "Korea hypertension fact sheet 2022 : analysis of nationwide population-based data with a special focus on hypertension in the elderly", Clin Hypertens, 29, pp.22~ (2023)[DOI]
- Kim S-Y, "Long term survival rate and prognostic factors of acute myocardial infarction", Korean Circ J, 29, pp.14~21 (1999)[DOI]
- Im JH, "Follow-up study on mortality in Korean stroke patients", J Korean Med Assoc, 54, pp.1199~1208 (2011)[DOI]
- "Korean heart failure fact sheet 2022", The Korean Society of Heart Failure, ~ (2022)
- Kim KM, "Impact of chronic kidney disease on mortality : a nationwide cohort study", Kidney Res Clin Pract, 38, pp.382~390 (2019)[DOI]
- Park C, "The uses and expenses of antihypertensive medications among hypertensive adults", Res Social Adm Pharm, 16, pp.183~189 (2020)[DOI]
- KOSIS, "Service KSI" (2023)
- KOSIS, "Service KSI" (2022)
- Robinson LA, "Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds", Health Policy Plan, 32, pp.141~145 (2017)[DOI]
- Johnson HM, "Antihypertensive medication initiation among young adults with regular primary care use", J Gen Intern Med, 29, pp.723~731 (2014)[DOI]